Procalcitonin as a Tool to Antimicrobial Stewardship in COVID-19 Patients with Superimposed Bacterial Infections: A Systematic Review

References

• Vanhomwegen C, Veliziotis I, Malinverni S, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. Ir J Med Sci. 2021;190:1649–1652. doi:10.1007/s11845-020-02485-z
   PubMed Web of Science ®Google Scholar
• Atallah NJ, Warren HM, Roberts MB, et al. Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: a case-control study. PLoS One. 2022;17(1):e0262342. doi:10.1371/journal.pone.0262342
   PubMed Web of Science ®Google Scholar
• Richards O, Pallmann P, King C, et al. Procalcitonin increase is associated with the development of critical care-acquired infections in COVID-19 ARDS. Antibiotics. 2021;10:1425. doi:10.3390/antibiotics10111425
   Web of Science ®Google Scholar
• May M, Chang M, Dietz D, et al. Limited utility of procalcitonin in identifying community-associated bacterial infections in patients presenting with coronavirus disease 2019. Antimicrob Agents Chemother. 2021;65(4):e02167–20. doi:10.1128/AAC.02167-20
   PubMed Web of Science ®Google Scholar
• Moreno-García E, Puerta-Alcalde P, Letona L, et al. Bacterial co-infection at hospital admission in patients with COVID-19. Int J Infect Dis. 2022;118:197–202. doi:10.1016/j.ijid.2022.03.003
   PubMed Web of Science ®Google Scholar
• He S, Liu W, Jiang M, et al. Clinical characteristics of COVID-19 patients with clinically diagnosed bacterial co-infection: a multi-center study. PLoS One. 2021;16(4):e0249668. doi:10.1371/journal.pone.0249668
   PubMed Web of Science ®Google Scholar
• Ming K, Myall AC, Hernandez B, et al. Informing antimicrobial management in the context of COVID-19: understanding the longitudinal dynamics of C-reactive protein and procalcitonin. BMC Infect Dis. 2021;21:932. doi:10.1186/s12879-021-06621-7
   PubMed Web of Science ®Google Scholar
• Pink I, Raupach D, Fuge J, et al. C -reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection. 2021;49:935–943. doi:10.1007/s15010-021-01615-8
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information.. Superimposed infection (concept ID: C0038826) - MedGen. U.S. National Library of Medicine; [cited August 21, 2022]. Available from: https://www.ncbi.nlm.nih.gov/medgen/11659#top. Accessed October 26, 2022.
   Google Scholar
• Critical Appraisal Skills Programme. CASP Cohort Study Checklist; 2018. Available from: https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP-Cohort-Study-Checklist-2018_fillable_form.pdf. Accessed October 26, 2022.
   Google Scholar
• Critical Appraisal Skills Programme. CASP Case-Control Study Checklist; 2018. Available from: https://casp-uk.b-cdn.net/wp-content/uploads/2018/03/CASP-Case-Control-Study-Checklist-2018_fillable_form.pdf. Accessed October 26, 2022.
   Google Scholar
• Basnet A, Chand AB, Shrestha LB, et al. Co-infection of uropathogenic Escherichia coli among COVID-19 patients admitted to a tertiary care centre: a descriptive cross-sectional study. J Nepal Med Assoc. 2022;60(247). doi: 10.31729/jnma.7376
   Web of Science ®Google Scholar
• Cheng K, He M, Shu Q, Wu M, Chen C, Xue Y. Analysis of the risk factors for nosocomial bacterial infection in patients with COVID-19 in a tertiary hospital. Risk Manag Healthc Policy. 2020;13:2593. doi:10.2147/RMHP.S277963
   PubMed Web of Science ®Google Scholar
• Waris A, Din M, Iqbal N, et al. Evaluation of serum procalcitonin level as a biomarker for disease severity in COVID-19 patients. New Microbes New Infect. 2021;43:100922. doi:10.1016/j.nmni.2021.100922
   PubMed Web of Science ®Google Scholar
• Hughes S, Mughal N, Moore LS. Procalcitonin to guide antibacterial prescribing in patients hospitalised with COVID-19. Antibiotics. 2021;10(9):1119. doi:10.3390/antibiotics10091119
   Web of Science ®Google Scholar
• Peters C, Williams K, Un EA, et al. Use of procalcitonin for antibiotic stewardship in patients with COVID-19: a quality improvement project in a district general hospital. Clin Med. 2021;21(1):e71. doi:10.7861/clinmed.2020-0614
   PubMed Web of Science ®Google Scholar
• Heer RS, Mandal AK, Kho J, et al. Elevated procalcitonin concentrations in severe Covid-19 may not reflect bacterial co-infection. Ann Clin Biochem. 2021;58(5):520–527. doi:10.1177/00045632211022380
   PubMed Web of Science ®Google Scholar
• Roy A, Powers HR, Craver EC, Nazareno MD, Yarrarapu SN, Sanghavi DK. Antibiotic stewardship: early discontinuation of antibiotics based on procalcitonin level in COVID‐19 pneumonia. J Clin Pharm Ther. 2022;47(2):243–247. doi:10.1111/jcpt.13554
   PubMed Web of Science ®Google Scholar
• Tang ML, Li YQ, Chen X, et al. Co-infection with common respiratory pathogens and SARS-CoV-2 in patients with COVID-19 pneumonia and laboratory biochemistry findings: a retrospective cross-sectional study of 78 patients from a single center in China. Med Sci Monit. 2021;27:e929783–1. doi:10.12659/MSM.929783
   PubMed Web of Science ®Google Scholar
• Garrido P, Cueto P, Rovira C, et al. Clinical value of procalcitonin in critically ill patients infected by SARS-CoV-2. Am J Emerg Med. 2021;46:525–531. doi:10.1016/j.ajem.2020.11.011
   PubMed Web of Science ®Google Scholar
• Heesom L, Rehnberg L, Nasim-Mohi M, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist. 2020;22:782. doi:10.1016/j.jgar.2020.07.017
   PubMed Web of Science ®Google Scholar
• Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to distinguish viral from bacterial pneumonia: a systematic review and meta-analysis. Clin Infect Dis. 2020;70(3):538–542. doi:10.1093/cid/ciz545
   PubMed Web of Science ®Google Scholar
• Melendi GA, Laham FR, Monsalvo A, et al. Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants. Pediatrics. 2007;120(2):e410–5. doi:10.1542/peds.2006-3283
   PubMed Web of Science ®Google Scholar
• Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis. 2004;39(2):206–217. doi:10.1086/421997
   PubMed Web of Science ®Google Scholar
• Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102–1110. doi:10.1164/rccm.201408-1483OC
   PubMed Web of Science ®Google Scholar
• Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chim Acta. 2020;505:190. doi:10.1016/j.cca.2020.03.004
   PubMed Web of Science ®Google Scholar
• Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Evid Based Child Health. 2013;8(4):1297–1371. doi:10.1002/ebch.1927
   PubMedGoogle Scholar
• Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ open. 2013;3(2):e002186. doi:10.1136/bmjopen-2012-002186
   PubMed Web of Science ®Google Scholar
• Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008;177(5):498–505. doi:10.1164/rccm.200708-1238OC
   PubMed Web of Science ®Google Scholar